Isis Pharmaceuticals Inc. Reaches New 12-Month High at $36.38 (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS)’s share price reached a new 52-week high during trading on Thursday, Stock Ratings Network.com reports. The stock traded as high as $36.38 and last traded at $36.29, with a volume of 4,072,272 shares traded. The stock had previously closed at $31.80.
A number of analysts have recently weighed in on ISIS shares. Analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $23.00 to $27.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock. Separately, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note to investors on Wednesday, September 4th. They set a “neutral” rating and a $26.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Isis Pharmaceuticals (NASDAQ:ISIS) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, August 20th. They now have a $27.00 price target on the stock.
Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $29.20.
In other Isis Pharmaceuticals news, COO B Lynne Parshall unloaded 63,505 shares of the stock on the open market in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $31.04, for a total transaction of $1,971,195.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Isis Pharmaceuticals has a 1-year low of $7.56 and a 1-year high of $34.31. The stock’s 50-day moving average is $27.93 and its 200-day moving average is $23.7. The company’s market cap is $4.184 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. On average, analysts predict that Isis Pharmaceuticals will post $-0.56 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.